• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Fatigue - Pipeline Review, H1 2012 Product Image

Fatigue - Pipeline Review, H1 2012

  • Published: March 2012
  • 76 pages
  • Global Markets Direct

Fatigue – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Fatigue - Pipeline Review, H1 2012', provides an overview of the Fatigue therapeutic pipeline. This report provides information on the therapeutic development for Fatigue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fatigue. 'Fatigue - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fatigue.
- A review of the Fatigue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fatigue Overview
Therapeutics Development
An Overview of Pipeline Products for Fatigue
Fatigue Therapeutics under Development by Companies
Fatigue Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Fatigue Therapeutics – Products under Development by Companies
Fatigue Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Fatigue Therapeutics Development
Bristol-Myers Squibb Company
Sanofi-Aventis
Hemispherx Biopharma, Inc.
MultiCell Technologies, Inc.
Chelsea Therapeutics, Inc.
Maywufa Company Limited
Fatigue – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Northera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-945429 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ampligen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCT-125 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHN011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHN012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHN013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Armodafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nuvigil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Testosterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Melatonin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XRP6976 + Modafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Armodafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Megestrol Acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nuvigil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Modafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
3,4-Diaminopyridine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-Carnitine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anakinra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fatigue Therapeutics – Drug Profile Updates
Fatigue Therapeutics – Discontinued Products
Fatigue Therapeutics - Dormant Products
Fatigue – Product Development Milestones
Featured News & Press Releases
Jan 11, 2012: FDA Grants Hemispherx Extension In Its Pending New Drug Application For Treatment Of Chronic Fatigue Syndrome
Dec 14, 2010: Hemispherx Receives FDA Extension For Pending NDA Of Chronic Fatigue Syndrome Treatment
Nov 29, 2010: Hemispherx Requests FDA For Extension Of Time For Ampligen NDA Submission
Nov 22, 2010: Hemispherx Announces Publication Of New Data On Ampligen’s Activity In Chronic Fatigue Syndrome In Journal Of Applied Research
Aug 19, 2010: Chelsea Initiates Investigator-Led Phase II Study Of Droxidopa In Chronic Fatigue Syndrome
Jun 14, 2010: MultiCell Retains CDSS To Manage MCT-125 Phase IIb Clinical Trial For PMSF In UK
May 19, 2009: Addition Of Lyrica Significantly Improved Generalized Anxiety Disorder Symptoms In Patients Who Responded Only Partially To Previous GAD Treatments
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Fatigue, H1 2012
Products under Development for Fatigue – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Bristol-Myers Squibb Company, H1 2012
Sanofi-Aventis, H1 2012
Hemispherx Biopharma, Inc., H1 2012
MultiCell Technologies, Inc., H1 2012
Chelsea Therapeutics, Inc., H1 2012
Maywufa Company Limited, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Fatigue Therapeutics – Drug Profile Updates
Fatigue Therapeutics – Discontinued Products
Fatigue Therapeutics – Dormant Products
Fatigue Therapeutics – Dormant Products (Contd..1)

List of Figures
Number of Products under Development for Fatigue, H1 2012
Products under Development for Fatigue – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos